Company Overview and News

4
This High-Yielding Sleep Well Investment Is About To Announce A Dividend Increase

11h seekingalpha
I am predicting another monthly dividend increase to $0.195 per month to be announced before the company reports earnings on August 2, 2018, for the reasons discussed in this article.
CLA MCQ TCAP KAP MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC

1
American Financial downgraded to market perform from outperform at Raymond James

2018-07-12 marketwatch
Ares Capital Corp. is a business development company that seeks investment opportunities in middle market companies with EBITDA of $10 - $250 million located in the US. The fund targets companies operating across a broad range of sectors, including healthcare services, business services, education, energy, financial services, consumer products, restaurants & food services, containers & packaging, automotive services, manufacturing, retail, aerospace & defense and chemicals.
ARU ARCC AFC

5
BDC CEF: High Yield Play Or Wealth Destroyer?

2018-07-11 seekingalpha
The distribution is well-covered and they haven't relied on capital resources or equity offerings to sustain the high yield.
HUSV ARU FGB ARCC FCM CYS.PRA CYS.PRB HDMV FOVCX FEO NMFC CYS

45
I Recently Purchased This 10% Yielding BDC

2018-06-28 seekingalpha
TCPC is likely under-priced for the reasons discussed in this article, trading under book value, RSI of 38, and offering a well-supported 10% dividend yield.
AIY AINV CLA MCQ TCAP KAP MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC AIB HTGX NMFC HTGY CNO OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC

77
Global Recession Risk Rising

2018-06-27 seekingalpha
Global recession risk rises as both China and Europe warn of collateral damage from trade tariffs.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR T ROKU CLDT VZ WPC OHI

34
Drop in Asset Coverage Ratio to Aid Ares Capital Financials?

2018-06-26 zacks
Ares Capital Corporation’s (ARCC - Free Report) board of directors approved to lower the minimum asset coverage ratio to 150% from 200%, as per the amendment in the Investment Company Act of 1940 by the Small Business Credit Availability Act. The amendment is subject to certain approval, timing and disclosure requirements. The effective date, from which the ratio will be lowered, is Jun 21, 2019. Notably, the debt/equity ratio ceiling of 1.
CMFN ARCC EPC KMI.WS SM ARES.PRA WHFBL ARES WHF ARU SLRC KMI.PRA KMI ZAGG KMR SLRA CVB KMRFZ

35
10% Yield And 18% Discount To Book: Priced For Upcoming Credit Issues?

2018-06-26 seekingalpha
My primary concern is the amount of investments that “require close monitoring”, which has increased from 6% to 21% of the portfolio over the last two quarters.
CLA MCQ TCAP KAP MCV PFLT OSLE MM CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA FDMCF MCC ARCC HCAPL GBDC MMCC EVEP FSIC FDUS MAIN TCC TCPC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC

67
Grow Your Income Even When Your Stocks Don't Increase The Dividend

2018-06-23 seekingalpha
There's a way we can give ourselves a raise, even when a company doesn't give us one.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR SIR ROKU CLDT VZ WPC OHI

30
Upcoming Book Value Declines For This Higher Yielding BDC?

2018-06-20 seekingalpha
Two of PSEC's largest investments will likely have upcoming writedowns, especially given that company has a fiscal year-end June 30, requiring a full audit.
CLA MCQ TCAP KAP PNNT MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC PSEC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA

25
Prospect Capital's Dividend And NAV Sustainability Analysis - Part 2 (Including September-October 2018 Dividend Projection)

2018-06-18 seekingalpha
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB

63
Will Rising Rates Derail This 11.95% Yielding REIT?

2018-06-16 seekingalpha
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI

12
Ares Capital Corp.: Time To Buy This 9.1%-Yielding BDC?

2018-06-15 seekingalpha
Ares Capital Corp. is no longer overbought, shares now sell for about net asset value again.
ARU ARCC

25
TPG Specialty Lending's NAV Sustainability And Investment Rating Analysis (Post Q1 2018 Earnings)

2018-06-14 seekingalpha
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ARU / Ares Capital Corp. 5.875% Bond Due 10/1/2022 on message board site Silicon Investor.

Aruba Networks (ARUN) Turnarund Investing
ARU.V Aurelian Resources Inc ARUR - American Resources Technologies, Inc. (Bullu0027s Board)
Santarus (SNTS) Subaru
CNBCu0027s Michelle Carusa-Cabrera Hotter then HOT The Kobiashi Maru Scenario
MARUM RESOURCES ON ALBERTA SRUN : STARUNI CORP -- Hot new ISP in California
CUSIP: 04010L608